Every 8-K that Rallybio Corporation (RLYB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RLYB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLYB filings page.
Rallybio Corp (RLYB) reported a change in the work arrangement of its Chief Financial Officer, Jonathan LieberSeptember 15, 2026base salary of $420,000Avenzo Therapeutics, Inc.May 31, 2026
Rallybio Corporation announced a definitive agreement to acquire Avenzo Therapeutics in an all‑stock reverse‑triangular merger combined with a $215.0 million concurrent private financing. Avenzo will become a wholly owned Rallybio subsidiary, and the combined company is expected to be renamed Avenzo Therapeutics and trade on Nasdaq as “AVZO.”
Based on an implied valuation of $15.0 million for Rallybio and $300.0 million for Avenzo and assuming Rallybio distributes substantially all pre‑closing net cash, pre‑transaction Rallybio equityholders are expected to own about 2.8% of the combined company and pre‑transaction Avenzo equityholders, including financing investors, about 97.2%, on a fully diluted treasury‑stock basis.
Rallybio stockholders will also receive contingent value rights tied to potential future proceeds from legacy asset dispositions. The combined company expects its cash at closing, including the $215.0 million financing, to fund operations into late 2028 and advance four clinical‑stage oncology programs through multiple Phase 1 updates and the start of several Phase 2 studies.
Rallybio Corporation’s planned merger with Candid Therapeutics will not proceed after Candid ended their agreement and signed a Permitted Alternative Agreement with UCB S.A. Instead of completing the transaction, Rallybio is entitled to receive a $50,000,000 Parent Termination Fee from Candid under the merger terms.
Rallybio, Candid and UCB also signed a waiver on May 1, 2026 that adjusts certain notice rights, allows payment of the termination fee and expense reimbursements on the first business day after termination, and includes broad mutual releases of claims related to the merger agreements and contemplated transactions. Rallybio plans to withdraw its previously filed Form S-4 registration statement.
Rallybio Corporation reported that Chief Medical Officer Steven Ryder, M.D., who has served in that role since January 2019, has left the company effective immediately. His departure occurs as Rallybio pursues a pending business combination with Candid Therapeutics, Inc. under a previously announced merger agreement.
Under a new separation agreement, Dr. Ryder will receive severance payments and benefits consistent with a termination by Rallybio without cause, as outlined in his existing employment agreement. After the closing of the Candid merger and related change of control, he is entitled to additional severance owed for a without-cause termination following a change of control, reduced by the initial severance amounts already paid.
Rallybio states that Dr. Ryder’s restricted stock, stock options and other equity awards will remain outstanding and may continue to vest according to the merger agreement. These awards will remain exercisable until 90 days following the closing of the merger, providing a limited post-closing window for exercise.
Rallybio Corporation agreed to merge with clinical-stage biotech Candid Therapeutics in a stock deal that will leave Candid’s investors owning the vast majority of the combined company. A concurrent private financing will provide $505.5 million of new capital to support Candid’s T‑cell engager pipeline for autoimmune diseases.
Based on agreed valuations and assuming Rallybio net cash of $37.5 million, pre‑transaction Rallybio holders are expected to own about 3.65% of the combined company, while Candid holders (including new investors) will own about 96.35%. The new entity will be renamed Candid Therapeutics, Inc. and is expected to trade on Nasdaq under ticker “CDRX”.
Rallybio stockholders will receive contingent value rights tied to cash proceeds from dispositions of Rallybio’s legacy assets. Closing requires shareholder approvals, an effective Form S‑4, completion of at least $200 million of the financing, Nasdaq listing approvals and antitrust clearance, among other customary conditions. Rallybio also reports it has regained compliance with Nasdaq’s minimum bid price rule following a 1‑for‑8 reverse stock split.
Rallybio Corporation approved and scheduled a 1-for-8 reverse stock split of its common stock. The split will become effective at 12:01 a.m. Eastern Time on February 6, 2026, after which the stock will trade on a post-split basis under a new CUSIP.
Stockholders approved the amendment at a special meeting, with 34,507,021 votes in favor, 464,514 against, and 11,939 abstentions. As of the December 30, 2025 record date, 42,243,774 shares were outstanding and entitled to vote, and 34,983,474 shares were represented, constituting a quorum.
Rallybio Corporation (RLYB) furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company noted that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act, which limits potential liability and incorporation by reference unless specifically stated.
Rallybio Corporation received an additional grace period from Nasdaq to fix a share price problem that threatens its stock market listing. After its common stock traded below the required $1.00 minimum closing bid price for 30 straight business days and failed to recover by the initial August 25, 2025 deadline, Nasdaq approved the company’s transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market.
The transfer took effect at the opening of business on August 29, 2025, and the stock continues to trade under the symbol “RLYB”. Rallybio now has until February 23, 2026 to regain compliance with Nasdaq’s bid price rule. The company plans to monitor its share price and is considering options to restore compliance, including a potential reverse stock split if needed.
If Rallybio does not meet the minimum bid price requirement by the new deadline, Nasdaq may move to delist the stock, although the company would have the right to appeal that decision to a Nasdaq Hearings Panel.
Rallybio Corporation (NASDAQ: RLYB) has divested its 50 % ownership in RE Ventures I, LLC (the ENPP1 joint venture) to Recursion Pharmaceuticals for immediate and potential future consideration.
- Initial consideration: Recursion issued 1,457,952 Class A shares (VWAP $5.1442) valued at $7.5 million on 8 July 2025.
- Make-whole mechanism: If Rallybio’s net proceeds from selling the Initial Shares differ from $7.5 million, the party benefiting must true-up the difference in cash.
- Contingent equity: Upon achievement of specified development milestones for the ENPP1 compound, Rallybio may receive additional shares worth up to $12.5 million, with the same make-whole feature.
- Milestone & royalty stream: The agreement grants Rallybio undisclosed cash milestone payments and low-single-digit royalties on future net sales of ENPP1-related products.
- Following the sale, the ENPP1 JV becomes an indirect wholly-owned subsidiary of Recursion; Rallybio relinquishes all equity interest.
The transaction strengthens Rallybio’s liquidity with $7.5 million in equity that can be monetised, de-risks ongoing ENPP1 development costs, and leaves upside through contingent consideration and royalties. However, future value now depends on milestones achieved by Recursion, and Rallybio forgoes direct participation in the JV’s long-term upside.
Rallybio (NASDAQ:RLYB) filed an 8-K announcing a new employment agreement with Chief Medical Officer Steven Ryder, M.D.
Key terms
- Base salary: $531,227
- Annual target bonus: 40% of salary
- Initial one-year term with automatic one-year renewals
- Standard severance: 12 months salary, prior bonus and up to 12 months COBRA
- Change-in-control severance: 1.5× salary + target bonus, 18 months COBRA and full vesting of time-based equity
Severance requires a release of claims; a 12-month non-compete and non-solicitation applies. No other operational or financial updates were disclosed.